Key insight into ongoing challenges and unmet needs in non-small cell lung cancer treatment, including specific patient populations and potential solutions through clinical trials.
Videos
Mitchell Smith, MD, PhD, discusses the ECOG-ACRIN E1411 trial among patients with previously untreated mantle cell lymphoma.
Jeremy Abramson, MD, discusses findings from the TRANSFORM study of lisocabtagene maraleucel vs standard of care treatment in patients with relapsed or refractory large B-cell lymphoma.
Cyrus M. Khan, MD, discusses the eligibility criteria of a phase 1/2 study evaluating glofitamab for the treatment of patients with large B-cell lymphoma, and provides data from the expansion cohorts of the trial.
Amer Zeidan, MBBS, MHS, reviews recent luspatercept and imetelstat data from the COMMANDS and IMerge clinical trials in lower-risk myelodysplastic syndrome.
Eirwen M. Miller, MD, discusses novel biomarkers that she believes will be important for endometrial cancer in the future.
Sandra M. Swain, MD, FACP, FASCO, reviews clinical trial data and how they inform the evolving treatment landscape in HER2+ early breast cancer.
Chirag Shah, MD, discusses the challenges in predicting the risk of local recurrence in patients with ductal carcinoma in situ, and what led to the DCISionRT test.
Cyrus M. Khan, MD, discusses pirtobrutinib for the treatment of mantle cell lymphoma and findings from the phase 1/2 BRUIN study.
Hatem Soliman, MD, discusses some of the exciting research that is ongoing for patients with HER2-positive breast cancer.
Heather Wakelee, MD, discusses the efficacy findings from the phase 3 KEYNOTE-671 clinical trial evaluating the addition of pembrolizumab to neoadjuvant platinum-based chemotherapy followed by resection and adjuvant pembrolizumab alone for patients with early-stage non–small cell lung cancer.
Benny Weskler, MBA, MD, FACS, FACCP, discusses the introduction of immune checkpoint inhibitors in the neoadjuvant setting for patients with non–small cell lung cancer.
Qian Wang, MD, MPH, discusses the progress of research into the molecular pathways responsible for developing small cell lung cancer.
Rebecca A. Shatsky, MD, looks to the future of biomarker testing in metastatic breast cancer and offers advice to community oncologists.
A medical oncologist discusses challenges with conducting molecular testing and reviews clinical trials focused on biomarkers for patients with ER+/HER2- metastatic breast cancer.
A review of results from the EMERALD trial investigating elacestrant in patients with ESR1-mutated metastatic breast cancer.
Rebecca A. Shatsky, MD, reviews biomarker testing guideline recommendations for patients with breast cancer and discusses testing practices upon progression.
An expert on breast cancer provides clinical insights on liquid and tissue biopsies for patients with metastatic disease.
Omar Mian, MD, PhD, provides an overview of the RAD-SG trial of RADiation therapy given with sacituzumab govitecan for bladder preservation in patients with muscle-invasive bladder cancer, which is currently in progress.
Focused conversation on precision medicine, including MMR testing, advanced treatment options, and the potential for non-surgical approaches in gastrointestinal malignancies.
Tracy Proverbs-Singh, MD, and Steven Lee-Kong, MD, discuss recent updates in the management of gastrointestinal malignancies, with a focus on colorectal cancer and the crucial role of precision medicine in guiding treatment decisions.
A medical oncologist discusses molecular biomarkers identified in patients with metastatic breast cancer and compares ESR1 with other genetic mutations.
Warren C. Swegal, MD, discusses the safety and tolerability of tyrosine kinase inhibitors for patients with radioactive iodine–refractory differentiated thyroid cancer.
Yann-Alexandre Vano, MD, discusses some of the exciting data being seen in the renal cell carcinoma space.
Marcia S. Brose, MD, PhD, FASCO, discusses the landscape of thyroid cancer by explaining the complexities and promising advancements seen in the space.
Zev A. Wainberg, MD, discusses the pressing relevance of the outcomes of the NAPOLI 3 trial, which were presented at the 2023 Gastrointestinal Cancers Symposium.
Justin Taylor, MD, discusses the treatment landscape for chronic lymphocytic leukemia and background on his early research assessing NX-2127 for this patient population.
Discover the potential of tisotumab vedotin combinations and emerging treatment strategies in the evolving landscape of cervical cancer management.
Ramez N. Eskander, MD, discusses the importance of understanding and managing treatment-related adverse events, including ocular side effects, bleeding, and neuropathy, associated with the innovative therapy tisotumab vedotin in cervical cancer patients.
Perspectives on the breakthrough antibody drug conjugate, tisotumab vedotin, its mechanism of action, and the significant clinical benefits it offers to patients with recurrent or metastatic cervical cancer, leading to FDA approval and promising results in a confirmatory trial.